Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Table 1 Patient characteristics

Characteristic	Patients with biomarker measurements	Patients without biomarker measurements	P value
ER positive and/or PR positive (n [%])	85 (58%)	159 (62%)	0.45^a
Prior adjuvant chemotherapy (n [%])	98 (60%)	161 (56%)	0.31^a
Objective response (complete or partial; n [%])	38 (24%)	66 (23%)	0.88^a
Median age (years)	54.9	57.2	0.25^b
Median follow up (years)	8.3	8.5	0.77^b
Median number of metastatic sites (n)	1	1	0.14^b
Median disease-free survival (months)	19	31	0.0003^b
Median time to progression (months)	4.1	4.3	0.62^c
Median overall survival (months)	12.6	12.3	0.81^c

Note that data regarding hormone receptor status and prior adjuvant chemotherapy were not available for all patients enrolled in CALGB 9342, and the total number is therefore less than 469 for some of the comparisons. ^a P value is based on the test for comparing two proportions. ^b P value is based on the Wilcoxon rank-sum test for comparing median values. ^c P value is based on a comparison of Kaplan-Meier curves with the log-rank test.

ISSN: 1465-542X